Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,5R,7R)-3-benzyl-7-(piperidin-1-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
74% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-(2-hydroxyethyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
71% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-(3-hydroxypropyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
23% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(1R)-2-hydroxy-1-phenylethyl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
31% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(2R)-1-hydroxy-3-phenylpropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
29% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
30% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxy-4-methylpentan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
71% inhibition at 0.02 mM
(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxypropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
35% inhibition at 0.02 mM
(1R,5R,7R)-N-(2-aminoethyl)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide
-
63% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-(1,4-diazepan-1-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
63% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-(morpholin-4-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
62% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-(thiomorpholin-4-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
58% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
34% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
48% inhibition at 0.02 mM
(1R,5S,7R)-3-benzyl-7-[[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
58% inhibition at 0.02 mM
(1R,5S,7S)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(R)-methylbutyl]amide
-
60% inhibition at 0.02 mM
(1R,5S,7S)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(S)-methylbutyl]amide
-
33% inhibition at 0.02 mM
(1S,5R,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid benzyl-(1-hydroxymethyl-3-methylbutyl)amide
-
35% inhibition at 0.02 mM
(1S,5R,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(R)-methylbutyl]amide
-
29% inhibition at 0.02 mM
(1S,5S,7S)-3-benzyl-7-(piperidine-1-carbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one
-
50% inhibition at 0.02 mM
1,2-epoxy-3-(4-nitrophenoxy)propane
acetyl-Phe-Ile-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl
-
transition-state peptidomimetic TS-41
acetyl-Trp-Phe-psi[OH-OH]-Phe-Trp-acetyl
-
transition-state peptidomimetic TS-49
acetyl-Trp-Ser-Phe-psi[OH-OH]-Phe-kynurenic acid
-
transition-state peptidomimetic TS-57
acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl
-
transition-state peptidomimetic TS-43
acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Val-acetyl
-
transition-state peptidomimetic TS-75
acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Val-Trp-acetyl
-
transition-state peptidomimetic TS-42
amprenavir
-
most effective inhibitor of Sap2, about 92% inhibition at 0.1 mM
Arg-Ile-Phe-psi[CH2-NH]-Phe-Gln-Arg
-
transition-state peptidomimetic TS-2
benzyloxycarbonyl-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe
-
benzyloxycarbonyl-L-Val-L-Val-((3R,4R)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-( (3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3R,4R)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-NH2
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OH
-
benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-OMe
-
benzyloxycarbonyl-L-Val-L-Val-statine-L-Ala-statine-OH
-
Diazoacetylnorleucine methyl ester
ethyl 4-[[(1R,5S,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]oct-7-yl]carbonyl]piperazine-1-carboxylate
-
74% inhibition at 0.02 mM
isovaleryl-Val-Val-statyl-Ala-statyl-OH
-
-
kynurenic acid-Dtg-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid
-
transition-state peptidomimetic TS-92
kynurenic acid-Dtg-Phe-psi[OH-OH]-Phe-phenoxyacetic acid
-
transition-state peptidomimetic TS-63
kynurenic acid-Thr-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid
-
transition-state peptidomimetic TS-93
kynurenic acid-Thr-Phe-psi[OH-OH]-Phe-kynurenic acid
-
transition-state peptidomimetic TS-59
kynurenic acid-Val-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid
-
transition-state peptidomimetic TS-94
kynurenic acid-Val-Phe-psi(S,R,S)[OH]-Phe-Val-kynurenic acid
-
transition-state peptidomimetic TS-91
kynurenic acid-Val-Phe-psi[OH-OH]-Phe-Val-kynurenic acid
-
best inhibitor; transition-state peptidomimetic TS-70
Lys-Ile-Phe-psi[CH2-NH]-Phe-Gln-Arg
-
transition-state peptidomimetic TS-23
mycogenic silver nanoparticles
-
phenylmethylsulfonyl fluoride
-
SDS
-
tolerated at 0.01% w/v, decrease of activity at 0.1% w/v, 1% completely destroys activity within a few min
t-butoxylcarbonyl-Phe-psi[OH-OH]-Phe-Dtg-phenoxyacetic acid
-
transition-state peptidomimetic TS-54
t-butoxylcarbonyl-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl
-
transition-state peptidomimetic TS-53
tert-butoxycarbonyl-Val-Val-(3R,4R)-4-amino-3-hydroxy-5-phenylpentanoyl-Ala-phenylstatyl-O-methyl ester
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-(3R,4R)-4-amino-3-hydroxy-5-phenylpentanoyl-OH
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-O-methyl ester
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-NH2
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-O-methyl ester
-
-
tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-OH
-
-
Trp-Ile-Phe-psi[CH2-NH]-Phe-Gln-Trp
-
transition-state peptidomimetic TS-10
Xan-Dtg-Val-psi(S,R,S)[OH]-Val-Dtg-Xan
-
transition-state peptidomimetic TS-90
(2R,3S)-phenylnorstatine
the 2R hydroxyl compound is 100- to 1000fold more potent than the 2S hydroxyl derivative
(2R,3S)-phenylnorstatine
the 2R hydroxyl compound is 100- to 1000fold more potent than the 2S hydroxyl derivative
(2R,3S)-phenylnorstatine
the 2R hydroxyl compound is 100- to 1000fold more potent than the 2S hydroxyl derivative
(2S,3S)-phenylnorstatine
the 2R hydroxyl compound is 100- to 1000fold more potent than the 2S hydroxyl derivative
(2S,3S)-phenylnorstatine
the 2R hydroxyl compound is 100- to 1000fold more potent than the 2S hydroxyl derivative
(2S,3S)-phenylnorstatine
the 2R hydroxyl compound is 100- to 1000fold more potent than the 2S hydroxyl derivative
(3S,4S)-phenylstatine
-
(3S,4S)-statine
-
1,2-epoxy-3-(4-nitrophenoxy)propane
-
not
1,2-epoxy-3-(4-nitrophenoxy)propane
Candida olea
-
not
1,2-epoxy-3-(4-nitrophenoxy)propane
-
-
Diazoacetylnorleucine methyl ester
-
not
Diazoacetylnorleucine methyl ester
Candida olea
-
-
Diazoacetylnorleucine methyl ester
-
not
mycogenic silver nanoparticles
-
after 24 h of incubation, significant reduction (87%) in metabolic activity is observed with 100 ppm mycogenic silver nanoparticles
-
mycogenic silver nanoparticles
-
after 24 h of incubation, significant reduction (74%) in metabolic activity is observed with 100ppm mycogenic silver nanoparticles
-
mycogenic silver nanoparticles
-
after 24 h of incubation, significant reduction (56%) in metabolic activity is observed with 100ppm mycogenic silver nanoparticles
-
mycogenic silver nanoparticles
-
after 24 h of incubation, significant reduction (80%) in metabolic activity is observed with 100ppm mycogenic silver nanoparticles
-
mycogenic silver nanoparticles
-
after 24 h of incubation, significant reduction (83%) in metabolic activity is observed with 100 ppm mycogenic silver nanoparticles
-
pepstatin
-
-
pepstatin
Candida olea
-
-
pepstatin A
IC50 for sap2p: 27 nM; IC50 for sap2p: 27 nM
pepstatin A
isozymes 1-10 except 7
pepstatin A
strong inhibitor; strong inhibitor
pepstatin A
-
potent inhibitor
ritonavir
-
saquinavir
-
additional information
-
methyl 2-diazoacetamidohexanoate
-
additional information
-
heavy metal ions; p-bromophenacyl bromide; SH-blocking reagents
-
additional information
-
not: soybean trypsin inhibitor; phenylmethylsulfonyl fluoride; tosyl-L-Phe chloromethyl ketone
-
additional information
cis-configured epoxides and aziridines containing hydrophobic moieties and amino acid esters as new potential inhibitors
-
additional information
-
cis-configured epoxides and aziridines containing hydrophobic moieties and amino acid esters as new potential inhibitors
-
additional information
-
isozyme Sap7 is not inhibited by pepstatin A, leupeptin, phenylmethylsulfonyl fluoride and EDTA
-
additional information
isozyme Sap7 is not inhibited by pepstatin A, leupeptin, phenylmethylsulfonyl fluoride and EDTA
-
additional information
isozyme Sap7 is not inhibited by pepstatin A, leupeptin, phenylmethylsulfonyl fluoride and EDTA
-
additional information
isozyme Sap7 is not inhibited by pepstatin A, leupeptin, phenylmethylsulfonyl fluoride and EDTA
-
additional information
isozyme Sap7 is not inhibited by pepstatin A, leupeptin, phenylmethylsulfonyl fluoride and EDTA
-
additional information
Candida olea
-
compounds inhibiting serine, thiol or metallo proteases
-
additional information
not inhibited by indinavir and nelfinavir; not inhibited by indinavir and nelfinavir
-
additional information
not inhibited by indinavir and nelfinavir; not inhibited by indinavir and nelfinavir
-
additional information
-
not inhibited by indinavir and nelfinavir; not inhibited by indinavir and nelfinavir
-
additional information
-
2-mercaptoethanol; diisopropyl fluorophosphate; DTT; EDTA; iodoacetamide
-
additional information
EDTA does not affect the proteolytic activity of the enzyme
-